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Reliable exclusion of prognostically significant coronary disease in left 
ventricular dysfunction by cardiac MRI. 
Abbreviations 
AHA, American Heart Association 
CAD, Coronary artery disease 
CMR, Cardiac magnetic resonance 
ESC, European Society of Cardiology  
HFREF, Heart failure with reduced ejection fraction 
HRA, Health Research Authority 
LAD, Left anterior descending 
LCx, Left circumflex artery 
LGE, Late gadolinium enhancement  
LV, Left ventricle 
LVEDVI, Left ventricular end diastolic index 
LVEF, Left ventricular ejection fraction 
LMS, Left main stem 
LVSD, Left ventricular systolic dysfunction 
MRCA, Magnetic resonance coronary angiography 
RCA, Right coronary artery 
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Introduction 
It is routine practice in patients presenting with a new diagnosis of left ventricular systolic dysfunction 
(LVSD) to exclude coronary disease as a cause.  This is because it is widely believed that patients 
with coronary disease and LVSD should be offered revascularisation.  Some studies such as the 
STITCH trial have questioned this philosophy, suggesting that patients with established LVSD and 
coronary artery disease (CAD) do not benefit from revascularisation (1).  Other studies have indicated 
that patients with significant viability benefit (2-4) and that patients with “prognostic” patterns of 
CAD should be offered revascularisation (5-10).  Although no universally agreed definition for 
prognostically significant coronary disease exists, revascularisation in patients may be recommended 
in patients with ischaemic LV dysfunction with reversible ischaemia and/or significant viability, even 
in the absence of angina (11-14). 
Invasive coronary angiography has traditionally been used for establishing the presence and pattern of 
coronary disease.   However it is invasive with a small morbidity and mortality and only identifies 
coronary disease causing luminal obstruction.  
Cardiac magnetic resonance (CMR) is an established non-invasive technique for assessing LV 
function accurately and determining the presence and extent of infarcts in the myocardium.  The 
presence of viability can also be readily determined with good evidence supporting the technique’s 
ability to predict benefit from revascularisation (15, 16).    
Yet, despite the potential advantages, late gadolinium enhancement (LGE) CMR has not gained 
widespread acceptance as a modality of choice to exclude prognostic CAD.  This is predominantly 
because the evidence for the predictive value of LGE CMR to detect CAD in LVSD is inconsistent 
with variable sensitivities depending upon the definition of CAD, the patient population, and the use 
of proximal coronary artery imaging (MRCA).  Whilst CMR using a combination of (LGE CMR) 
with proximal coronary artery imaging by MRCA  has been shown to accurately categorise the 
aetiology of heart failure as ascribed by a consensus panel (17), MRCA is not routinely available in 
many centres, is time consuming to perform and image quality is unreliable.  LGE CMR without 
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MRCA is a sensitive and specific marker of single vessel CAD in heart failure for those with a 
previously diagnosed myocardial infarction (18), however, the sensitivity is lower for those without a 
history of myocardial infarction (80-95%) (19-21).  Whilst such false negative rates may be 
acceptable for non-prognostic single vessel disease, they may not good enough for the routine 
exclusion of prognostic CAD.  The evidence for the predictive value of LGE CMR alone to detect 
prognostic CAD in heart failure is lacking and may account for its underutilisation. 
This study aimed to assess the ability of late gadolinium CMR alone to exclude prognostically 
significant CAD in patients with LVSD. 
Materials and Methods 
Patient Population 
We retrospectively identified individuals who had undergone both CMR and X-ray angiography since 
2006 until April 2013.  The European Society of Cardiology (ESC) imaging criteria for the diagnosis 
of heart failure with reduced ejection fraction (HFREF) was applied (11, 22).  Those with LV ejection 
fraction (LVEF) <50% or LV end diastolic volume index (LVEDVI) ≥97 mL/m2 on CMR, or with a 
previous echocardiogram suggesting LV systolic impairment for which CMR had been requested to 
further differentiate the cardiomyopathy were selected.  Of these 143 individuals, those with a history 
of previous revascularisation (n=23), and those who did not receive gadolinium at the time of CMR 
(n=4) were excluded.  A final total of 116 patients were included for data analysis.  The sequence of 
investigations was not defined so that CMR could take place both before or after the X-ray 
angiogram.  The CMR scan was reported by an imaging consultant independently of the X-ray 
angiogram.  The study was considered by the NHS Health Research Authority (HRA) Screening Tool 
as not requiring individual patient consent. 
4 
 
Cardiac Magnetic Resonance 
CMR images were obtained using a 1.5 Tesla GE Signa Excite scanner.  Following scout images, 
ECG-gated, steady-state, free precession breath-hold sequences (typical echo time/repetition time 
1.3/3.1 ms, flip angle 45
o
 ) were performed to produce three long-axis cines and sequential short axis 
cines (8mm slices with 2mm gaps) from the atrioventricular ring to the apex of the heart.  The LGE 
images were acquired 10 minutes after intravenous gadolinium-DOTA (Dotarem 0.2 mmol/kg) into a 
peripheral vein using an inversion recovery gradient-echo sequence.  Inversion times were 
individualised to null normal myocardium (typically 180 to 260ms; pixel size 1.4 x 1.3 mm) and 
identical views were obtained as for cine imaging except for the removal of basal short axis slices in 
the LV outflow tract.  The scan was reported by a consultant cardiologist with level 3 accreditation in 
CMR.  LVEF and LVEDVI were measured using the standard techniques with the inclusion of 
papillary muscles in LV volumes (23).  LGE was deemed to be present only when signal enhancement 
could be seen in two planes.  It was described as subendocardial, epicardial, transmural or midwall 
and reported according to the American Heart Association (AHA) 17 segment model in terms of the 
myocardial segments affected.  Subendocardial and transmural LGE was assumed to represent a 
myocardial infarction due to CAD.   
X-ray Coronary Angiography 
Invasive X-ray coronary angiography was reported by a consultant cardiologist on the same day as the 
X-ray angiogram procedure.  The presence and degree of any coronary stenoses were labelled on a 
detailed pictorial display of the coronary arteries along with a written description.  Prognostic 
coronary disease was defined as ≥50% left main stem disease, ≥75% proximal LAD stenosis, or ≥70% 
stenosis of any 2 or 3 main epicardial coronary arteries.  A main epicardial coronary artery was 
defined as the main LAD or large secondary branch, main Left Circumflex (LCx) or large secondary 
branch or main right coronary artery (RCA) excluding branches.  This definition was based upon 
combined European and American guidelines, along with other respected trial data that demonstrated 
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survival benefits in a general or heart failure population when such guideline definitions lacked clarity 
(5, 8, 12, 14, 24, 25). 
Data Analysis 
LGE CMR and X-ray angiogram reports were reviewed independently of each other.  The definition 
of prognostic CAD was applied to the X-ray angiogram reports forming two groups: those with 
prognostic CAD and those without.  The presence or absence of subendocardial LGE was determined 
from the CMR report and two groups were established: those with subendocardial LGE and those 
without.  The presence and quantity of subendocardial LGE was determined for each of the 17 AHA 
segments (0.5 = <50%, 1 = 50 to 100% segment thickness affected) and then the total amount of 
subendocardial LGE calculated for each scan to produce a LGE total score.  Differences in patient 
characteristics between those with and without prognostic CAD were assessed using the Student’s t 
test, Mann-Whitney U test, or Fisher’s exact test depending upon the continuous nature and 
distribution of the data.  Continuous variables were expressed as mean ± standard deviation unless 
otherwise specified.  To analyse the accuracy of LGE CMR to detect prognostic CAD we assessed 
sensitivity, specificity, positive and negative predictive value with 95% confidence intervals, 
confirmed using exact methods (26, 27).  A LGE Score was calculated for each scan with a view to 
evaluating whether the total amount of LGE could help predict the likelihood of prognostic CAD in 
positive CMR scans.  A value of 1 was given for one AHA segment with transmural enhancement, 
and 0.5 for one AHA segment with <50% transmural enhancement.  A maximum Score of 17 would 
represent transmural LGE in every AHA segment.  The significance of this score was assessed using 
the Mann-Whitney U test. 
Results 
A total of 116 patients who had both CMR and X-ray angiography were included for the final 
analysis.  The baseline characteristics are shown in Table 1.  Mean age was 64 years and 78% were 
male.  Mean LVEF was 40% and LVEDVI  114 mL/m
2
.  The indication for CMR was varied, with 
the majority (79%) to investigate the aetiology of the LV dysfunction.  Other indications included 
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investigation of left ventricular hypertrophy, ventricular fibrillation/ventricular tachycardia, troponin 
positive chest pain and valve disease, all in association with LV dysfunction.  Patients with a previous 
history of revascularisation were excluded.   
Median time between CMR and angiogram was 42 days: in 41% of cases the CMR was performed 
before the X-ray angiogram.  The diagnostic performance of LGE CMR to predict prognostic CAD is 
demonstrated in Table 2 and Table 3.  The prevalence of prognostic CAD was 47% (95% CI 38 to 
57%).  The presence of ≥1 segment of subendocardial LGE detected prognostically significant CAD 
with a sensitivity of 100% (95% CI, 94 to 100%).  The negative predictive value was 100% (95% CI 
87 to 100%) and thus false omission rate (the chance of the condition being present amongst those 
with a negative test) was 0% (95% CI, 0 to 13%).  Specificity was 44% (95% CI 32 to 58%) with a 
false positive rate of 38% (95% CI 28 to 49%).   
The sub-analysis of those with false positive LGE CMR investigations demonstrated that 18 patients 
(53%) had single vessel, non-prognostic CAD that was severe enough to explain the infarct shown on 
LGE CMR.  In the remaining 16 cases (47%), the patients had normal coronaries or only minor CAD 
with no evidence of a likely culprit for a plaque event.   In some of these cases the pattern of LGE was 
in a single coronary artery territory distribution and in others LGE was present in a multi territory 
distribution.  The differential diagnosis for this group includes true myocardial infarction with 
recanalization of an occluded artery, coronary spasm, microvascular disease, emboli or infiltrative 
diseases such as cardiac sarcoid that can be associated with a subendocardial distribution of LGE.  
Rarely, artefact mimicking LGE would also account for some of these cases. 
The mean LGE Score for those with LGE and with prognostic CAD (6.0, SD 2.7) was compared with 
the mean LGE Score for those with LGE but without prognostic CAD (4.3, SD 3.2) (Table 4).  This 
demonstrated a significant difference between the LGE Scores (P=0.007) suggesting that those with 
smaller LGE scores are less likely to have prognostic CAD.  Indeed the 16 cases with LGE but normal 
or only minor CAD had a mean LGE Score of 1.9 (SD 1.4).   
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In the 27 patients with true negative results, i.e. non-prognostic coronary disease and no 
subendocardial LGE, LGE in a midwall or epicardial pattern was seen in 56% of patients.  Proposed 
aetiologies for the cause of LV systolic dysfunction in this group included idiopathic dilated 
cardiomyopathy, myocarditis, cardiac sarcoid, ARVC with LV involvement and vasculitis.  In one of 
these cases there was single vessel CAD with 100% occlusion of a coronary artery at X-ray 
angiography but no evidence of an infarct on LGE CMR.  Further exploration of this case revealed 
that the LGE CMR was performed four months before the X-ray angiogram and in the interim period 
the patient developed exertional chest pain followed by an episode that would be in keeping with a 
myocardial infarction clinically, and could explain the discrepancy between the imaging studies.   
Figure 1 demonstrates the combined X-ray angiography and LGE CMR images for a true positive, 
false positive and true negative case from this study.  Imaging for a false negative case is not provided 
as this scenario did not occur in this cohort.   
Discussion 
Our results demonstrate that LGE CMR reliably excludes prognostic CAD in patients with LV 
systolic dysfunction with 100% sensitivity and negative predictive value.   This would support CMR 
with LGE being used as a first line screening tool in this patient cohort, reserving invasive X-ray 
coronary angiography for those with subendocardial patterns of LGE.   
Specificity was low at 44% (95% CI 32 to 58%) with a false positive rate of 38% (95% CI 28 to 49%) 
that would necessitate invasive X-ray angiography.  However, this high false positive rate can be 
explained by significant single vessel CAD in over half of the cases which may help justify this rate 
of pursuing of invasive X-ray angiography.  The total LGE Score may aid as an additional helpful 
indicator of whether prognostic or indeed any significant CAD will be present on X-ray angiography 
but requires further investigation.  
There is no standard definition for prognostically significant CAD amongst the LGE CMR studies.  
Our definition for prognostic CAD is based on current guidelines and respected trial data (5, 8, 28) 
and excludes single vessel disease except for left main stem or proximal LAD disease.  Previous 
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groups that have shown moderate ability of LGE CMR to detect CAD used diagnostic thresholds that 
were less severe than our study and included non-prognostic single vessel disease (19, 20).  However, 
the argument to identify single vessel disease to inform changes to medical management by way of 
antiplatelet and lipid lowering therapy is contentious in a heart failure population (29, 30).  Those 
with 100% sensitivity have been in cohorts with confirmed myocardial infarctions (18) or have 
included CMR proximal coronary artery imaging in the protocol (17).  This is the first study to assess 
the utility of LGE CMR without proximal coronary artery imaging to detect prognostically significant 
CAD.  
The evidence supporting revascularisation in LV dysfunction is conflicting but it may improve 
survival in certain settings, providing justification for investigations to identify those who might 
benefit.  Whilst many centres still perform routine X-ray coronary angiography to identify CAD in 
newly diagnosed LV dysfunction, LGE CMR offers a non-invasive alternative with lower risks and 
the potential to improve the selection of those patients for whom revascularisation would be of 
benefit.  Limitations of LGE CMR in this setting include circumstances when CAD causes large areas 
of myocardium to be hibernating but without fibrosis or LGE.  Alternatively non-ischaemic causes of 
LV dysfunction can result in fibrosis and LGE in a subendocardial distribution that might raise false 
concerns about the presence of significant CAD.  Although both of these scenarios have been 
demonstrated in trials to date (21) and could result in false positive or false negative results, the 
clinical history in both these circumstances would likely inform alternate conclusions and lead to 
appropriate recommendations for invasive X-ray coronary angiography. 
In our study, there were no false negative results in a cohort with a high prevalence of prognostic 
CAD supporting the hypothesis we have tested.  This is a reassuring demonstration of how CMR 
scanning using gadolinium late enhancement protocols (without proximal coronary artery imaging) 
can be used as a screening tool to exclude prognostic CAD and avoid unnecessary invasive X-ray 
angiography.  It is an attribute of CMR which complements the other qualities of this imaging 
modality in the setting of LV dysfunction, including accurate measurements of left and right 
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ventricular volumes (31), assessment of pericardial and structural heart disease, and identification of 
myocardial inflammation or infiltration (18).  
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Limitations 
We acknowledge that the visual grading of vessel stenosis on X-ray angiography is subject to 
observer interpretation but it is nevertheless the standard method for assessment of the severity of 
coronary stenoses during routine diagnostic angiography studies.   
The study cohort is small and conclusions should be interpreted with this in mind.  A large 
prospective study is now needed to clarify if this high level of sensitivity can be reproduced in a 
generic newly diagnosed heart failure population using similar definitions for CAD.   
Conclusions 
The absence of subendocardial LGE on CMR reliably excluded prognostic CAD in patients with LV 
systolic dysfunction, supporting the use of this modality to avoid unnecessary invasive coronary 
angiography in this setting. 
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Table 1. Baseline Characteristics 
 
Characteristic Entire 
Group 
Prognostic 
CAD present 
Prognostic 
CAD absent 
P value 
Number of patients (%) 116 (100%) 55 (47%) 61 (53%)  
Age (± SD) 64 ± 9 67 ± 8 61 ± 10 P=0.001* 
Male Sex (%) 90 (78%) 47 (86%) 43 (71%) P=0.074*** 
Time between investigations  
(days ± IQR)  
42  
(20 to 83) 
41 
(21 to 57) 
44 
(17 to 123) 
P=0.619** 
CMR LVEF (%) (± SD) 40% ± 12 
 
41% ± 11 
 
39% ± 14 
 
P=0.573** 
CMR LVEDVI (mL/m
2
) (± SD) 114 ± 31 
(n=100) 
116 ± 33 
(n=46) 
112 ± 30 
(n=54) 
P=0.436** 
CAD, Coronary artery disease; CMR, Cardiac magnetic resonance; LVEF, Left ventricular ejection 
fraction; LVEDVI, Left ventricular end diastolic volume indexed to body surface area; IQR, Inter-
quartile range; SD, standard deviation.  *Students t test, **Mann-Whitney U test, ***Fisher’s Exact 
test. 
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Table 2. Diagnostic performance of LGE CMR to predict prognostic CAD 
 X-ray angiogram Total 
Prognostic CAD present Prognostic CAD absent 
CMR Subendocardial 
LGE present 
55   (TP) 34   (FP) 89 
Subendocardial 
LGE absent 
0   (FN) 27   (TN) 27 
Total 55 61 116 
CAD, Coronary artery disease; CMR, Cardiac magnetic resonance; LGE, Late gadolinium 
enhancement; TP, True positive; FP, False positive; FN, False negative; TN, True negative. 
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Table 3. Diagnostic parameters of LGE CMR to predict prognostic CAD 
 
 Performance of LGE CMR  (95% Confidence Interval) 
Prevalence of prognostic CAD 47% (38 to 57%) 
Sensitivity 100% (94 to 100%) 
Specificity 44% (32 to 58%) 
Positive Predictive Value 62% (51 to 72%) 
Negative Predictive Value 100% (87 to 100%) 
False Omission Rate 0% (0 to 13%) 
LGE CMR, Cardiac magnetic resonance with late gadolinium enhancement sequences; CAD, 
Coronary artery disease. Results confirmed by exact methods (26, 27).  
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Table 4. Comparison of mean LGE Scores for those with and without prognostic CAD   
 Entire Group Prognostic 
CAD present 
Prognostic 
CAD absent 
P value 
Subendocardial LGE present (%) 89 (77%) 55 (100%) 34 (56%)  
 
LGE Total Score  
(mean of all scans ± SD) 
 
4.1 ± 3.5 
 
6 ± 2.7 
 
2.4 ± 3.2 
 
 
P<0.001** 
 
LGE Total Score  
(mean of scans with LGE present ± 
SD) 
5.3 ± 3.0 6.0 ± 2.7 
(n=55) 
4.3 ± 3.2 
(n=34) 
P=0.007** 
 
CAD, Coronary artery disease; LGE, Late gadolinium enhancement; SD, standard deviation.  The 
maximum LGE Total Score = 17 if all segments are transmurally infarcted. **Mann-Whitney U test. 
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Figure 1.  X-ray angiography and associated LGE CMR images for true positive, false positive and 
true negative cases. 
Demonstration of three cases: Images A and B demonstrate a true positive case. Images C and D 
demonstrate a false positive case. Images E and F demonstrate a true negative case. There were no 
false negative cases in this cohort.  
Image A, Coronary angiogram demonstrating prognostic coronary artery disease with > 75% stenosis 
of the proximal left anterior descending (LAD) artery.  Image B, Cardiac magnetic resonance image, 
demonstrating transmural late gadolinium hyperenhancement in the mid anterior wall and >50% 
subendocardial hyperenhancement of the basal anterior wall.  This is consistent with an infarct in the 
LAD territory. 
Image C, Coronary angiogram, demonstrating normal appearance of the left sided coronary arteries 
other than distal branch obtuse marginal disease. Image D, Cardiac magnetic resonance image, 
demonstrating a localised segment of subendocardial hyperenhancement in the posterior wall.  The 
differential diagnosis includes a true myocardial infarction with recanalisation of an occluded artery, 
coronary spasm, small vessel disease or emboli.  Alternatively, Fabry’s disease or infiltrative diseases 
such as cardiac sarcoid should be considered.   
Image E, Coronary angiogram, demonstrating normal left sided coronary arteries.  Image F, Cardiac 
magnetic resonance 4-chamber image, demonstrating no evidence of hyperenhancement on late 
gadolinium imaging. 
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Figure 4 – Summary of all images 
 
 
